Compare prices and buy Prostamax from 4 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic tetrapeptide (Lys-Glu-Asp-Pro / KEDP) in the Khavinson short-peptide family, associated with prostate tissue. Russian cell and tissue-culture studies report effects on rat prostate explants and on chromatin in lymphocytes from elderly donors. Part of the Cytogen class. It has no FDA approval.
For research purposes only. Not medical advice.
Prostamax is a synthetic tetrapeptide, Lys-Glu-Asp-Pro (written KEDP), from Vladimir Khavinson's short-peptide program, catalogued with the rest of the family in Longevity and Bioregulators. The group's 2022 review in the International Journal of Molecular Sciences lists it as KEDP and labels it a regulator of prostatic functions, citing the group's European patent for the peptide. The family's other reproductive entry is Testagen, a different tetrapeptide.
That patent, EP1353939, filed in 2001 and granted in 2004 with Khavinson as first inventor, claims Lys-Glu-Asp-Pro as a peptide that regulates prostate function. It gives the formula C20H33N5O9 and a molecular weight of 487.51 without the acetate counter-ion, and PubChem's record under the name Prostamax has the same formula. The patent names Prostatilen, a polypeptide preparation extracted from animal prostate tissue, as its prototype.
The patent's own experiments are preclinical.
The family's proposed mechanism is direct binding to DNA. In melting experiments at the Institute of Macromolecular Compounds in St. Petersburg, KEDP and two other short peptides changed the melting temperature and stability of double-stranded DNA (Solovyev, International Journal of Biological Macromolecules, 2015). Computer docking by Khavinson and colleagues ranked KEDP second of 26 short peptides for predicted binding to the peptide transporter PEPT1 (Biomolecules, 2023), while the group's 2022 review states that it does not show high predicted binding to LAT1, an amino-acid transporter moderately expressed in the prostate.
The patent also describes two clinical series.
The patent reports less pain and better urine flow after treatment. Its tables give before-and-after figures for the treated men only, and it does not say how patients were assigned or report results for the comparison groups. A PubMed search in October 2026 found no other study of the peptide in people.
PeptideScouter found no FDA approval or compounding-list record for Prostamax. In a June 17, 2026 warning letter to the online seller Wholesale Peptide, FDA called Prostamax and gonadorelin unapproved new drugs. The agency based that on prostate and urinary claims on the product page, and stated that "research use only" and "not for human consumption" labeling did not change the products' intended use as drugs for human use.
As of October 21, 2026, Prostamax appears in none of these:
The published evidence is preclinical, apart from two clinical series in its developers' patent. Prostamax is the tetrapeptide Lys-Glu-Asp-Pro, which Vladimir Khavinson's group labels a regulator of prostatic functions, citing its 2004 European patent, EP1353939. In that patent, rats with chronic bacterial prostatitis given a 10-day course had lower prostate inflammation scores than untreated or saline-treated infected rats. A 2006 Russian study reported a stimulating effect on prostate tissue explants from young and aged rats. The patent's two clinical series did not report results for their comparison groups.
Only in two clinical series described in its developers' 2004 European patent, EP1353939. One gave the preparation to 35 men with chronic prostatitis and the other to 19 men with stage I or II prostate adenoma, each beside a smaller comparison group on conventional treatment. The patent reports less pain and better urine flow, but gives before-and-after figures for treated men only and does not say how patients were assigned. ClinicalTrials.gov lists no study under the name or the sequence KEDP as of October 2026, and a PubMed search found no other study of the peptide in people.
It holds no FDA approval. In a June 17, 2026 warning letter to the online seller Wholesale Peptide, FDA called Prostamax an unapproved new drug, based on prostate and urinary claims on the product page, and stated that research-use-only labeling did not change its intended use as a drug for human use. As of October 21, 2026, Prostamax does not appear in Drugs@FDA, in either table of FDA's Category 2 list of bulk drug substances raising significant safety risks, in FDA's lists of substances nominated for compounding under Sections 503A and 503B, or in the records of FDA's Pharmacy Compounding Advisory Committee meetings of October and December 2024 and July 2026. FDA's substance registry has no record of it.
No. Prostatilen is a polypeptide preparation extracted from animal prostate tissue. Prostamax is a single synthetic tetrapeptide, Lys-Glu-Asp-Pro, with the formula C20H33N5O9. The developers' 2004 European patent for the tetrapeptide names Prostatilen as its prototype and cites the extract's complicated production and variable physical and chemical properties as limits on its use.
Prostamax is sold by 4 research peptide vendors indexed on PeptideScouter, with 4 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
3 of the 4 indexed vendors currently have Prostamax in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Swiss Chems currently lists Prostamax at $3.00/mg, the lowest listed price across 4 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $2.70/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 4 vendors listing Prostamax publish a PeptideScouter code, worth 10% off. Applied, the lowest effective price falls from $3.00/mg listed to $2.70/mg at Swiss Chems. Each vendor's code is shown beside its price in the table above.
Prostamax ranges from $3.00/mg to $8.10/mg across 4 listings from 4 research peptide vendors, normalized to USD per milligram and refreshed daily.
4 research peptide vendors currently list Prostamax on PeptideScouter, with 3 in stock right now. We track 4 listings across size and kit variants.
